BS, MPH, DrPH, GradDipEco
Dr Sophy Shih is a health economist with demonstrated expertise in economic evaluation and health service research. She has extensive knowledge of designing and implementing trial-based economic assessments, performing economic evaluations, and building economic models. Dr Shih was trained in health economics, public health and biomedical science. She has worked on a broad range of topics including viral infection, rare genetic disease, cancer, diabetes, psycho-oncology, and disability with a focus on intervention research of prevention and screening.
In 2019, Dr Shih joined the SERP at the Kirby Institute and the NPESU at the Centre for Big Data Research in Health as a Senior Research Fellow/Health Economist. Her current working programs focus on HCV and HIV testing strategies and treatment uptake, and scaling up of point-of-care (POC) technology to enhance testing for HCV and HIV infection and reduce the mortality and morbidity of these infectious diseases.
Dr Shih was a subcommittee member of the Clinical Guidelines Network at Cancer Council Australia and co-authored the “Economics of Keratinocyte Cancer” chapter of the NHMRC endorsed clinical guidelines “Clinical Practice Guidelines for Keratinocyte Cancer”.
Dr Shih has collaborated with colleagues specialized in infectious diseases since she joined the Kirby Institute in 2019. Her current work on developing the health economics framework for point-of-care testing of infectious diseases will inform future infectious diseases control policy, including evaluation of a national program to scale-up hepatitis point-of-care (POC) testing and treatment; economic evaluation of the NSW dried blood spot (DBS) self-sampling HIV and HCV testing pilot program; an RCT investigating HCV POC testing to improve treatment uptake in people who inject drugs (the TEMPO study); cost-effectiveness analyses of HCV testing and treatment in NSW prisons, and the economic assessment of accelerating the uptake of initiatives to address HIV drug resistance surveillance in Papua New Guinea (ACTUP-PNG study). Dr Shih is a CI on an NHMRC partnership grant (ETHOS III study) to examine scale-up of point-of-care hepatitis C RNA testing in drug treatment clinics and a CI on the NSW Health funded study evaluating the dried blood spot (DBS) testing for HIV/HCV.